PIPELINE
LEAD
PROGRAMS
AU-409 for Liver Cancer
Status: Phase 1
Novel, first-in-class compound for liver cancer, which is the fastest growing cancer in the US and EU, and has a high prevalence in Asia.
AU-018 for Heart-Safe Chemotherapy
Status: IND enabling
Heart-safe chemotherapy for the $1B anthracycline chemotherapy market, to help improve tolerability and raise the standard of cancer care.
Our growing pipeline of novel cancer drug candidates
PRECLINICAL
DISCOVERY
DISEASE AREA*
CLINICAL
*Among 70+ diseases analyzed, in discovery or early preclinical stage
Classic
Diseases
Our focus is on advancing novel therapies that raise the standard of care for cancer patients, by generating more personalized treatments for cancers, cancer-related diseases, and subtypes of cancer we have yet to define.